Get In Touch
Have any questions or comments about the content you see on this page?
June 24, 2019
We were honored to sponsor the NORD (National Organization for Rare Diseases) Rare Impact Awards this past weekend and are honored to have been recognized with an Industry Impact Award for the development and approval of ONPATTRO (patisiran).
This year’s Rare Impact Awards gala took place as part of the 2019 Living Rare, Living Stronger NORD Patient and Family Forum in Houston, TX. This annual event brings together health care professionals, researchers and industry for a program of presentations, learning and networking.
Rick Falzone, Sr. Director of Clinical Operations accepted the award on Alnylam's behalf.
See the full list of Award winners here.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site